VACHHIGH SIGNALMANAGEMENT10-K

VACH has entered into a definitive business combination agreement with Swiss biotech company Veraxa Biotech AG, marking a significant strategic pivot from its blank-check acquisition phase.

This represents a major milestone for the SPAC as it transitions from capital-raising mode to executing its core business strategy through the proposed merger with Veraxa. The transaction involves creating complex Swiss and Cayman Islands entities as part of the deal structure, suggesting sophisticated cross-border considerations that investors should monitor closely for execution risks and regulatory approvals.

Comparing 2026-03-10 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

The company's financial position shows signs of strain with current assets declining substantially to $194K while total liabilities increased modestly to $13.3M, deepening the negative stockholders' equity position to -$13.1M. Operating cash flow improved meaningfully but remained negative at -$486K, indicating ongoing cash consumption during the transaction process. The overall picture reflects a SPAC under financial pressure to complete its business combination while managing limited liquidity.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
-72.8%
$712K→$194K

Current assets declined 72.8% — monitor working capital adequacy and short-term liquidity.

Operating Cash Flow
Cash Flow
+30.9%
-$703K→-$486K

Operating cash flow surged 30.9% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
-15.6%
-$11.4M→-$13.1M

Equity decreased 15.6% — buybacks or losses reducing book value, monitor solvency ratios.

Total Liabilities
Balance Sheet
+10.4%
$12.1M→$13.3M

Liabilities increased 10.4% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-03-10
PRIOR — 2025-03-31
ADDED
There were 25,300,000 Class A ordinary shares, par value $0.0001 per share, issued and outstanding and 6,325,000 Class B ordinary shares, par value $0.0001 per share, issued and outstanding as of March 10, 2026.
Certain Relationships and Related Transactions, and Director Independence.
Proposed Business Combination On April 22, 2025, we entered int a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the BCA ), with Veraxa Biotech AG, a company duly organized, validly existing, and in good standing under the laws of Switzerland ( Veraxa ) and Oliver Baumann, an individual, solely in his capacity as representative for the Company Shareholders.
Pursuant to the terms of the BCA, Voyager Acquisition Sponsor Holdco LLC, a Delaware limited liability company ( Sponsor ), will form a public limited company organized under the Laws of Switzerland ( PubCo whose legal name is referred to in the Joinder Agreement described below), and PubCo will form an exempted company limited by shares incorporated under the laws of the Cayman Islands, to be a direct wholly owned subsidiary of PubCo ( Merger Sub whose legal name is referred to in the Joinder Agreement described below, and, together with PubCo each, individually, an Acquisition Entity ).
Each such Acquisition Entity shall enter into a joinder to the BCA, in form and substance satisfactory to Veraxa.
+7 more — sign up free →
REMOVED
There were 25,300,000 Class A ordinary shares, par value $0.0001 per share, outstanding as of March 31, 2025.
We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us.
We will be required to evaluate our internal control procedures for the fiscal year ending December 31, 2024 as required by the Sarbanes-Oxley Act.
Holders As of December 31, 2024, there were eleven holders of record of our securities, one holder of record of our Class A ordinary shares, eight holders of record of our Class B ordinary shares, one holder of record of our Public Warrants and three holders of record of our Private Placement Warrants.
However, if our initial shareholders or management team acquire public shares in or after this offering, they will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to complete our initial business combination within the prescribed time period On January 24, 2024, the SEC adopted the 2024 SPAC Rules, which became effective on July 1, 2024.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →